Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

Claudia Allemani, Hannah K. Weir, Helena Carreira et al. · The Lancet · 2014 · 2.7K citations · Full text

Medicine, Biostatistics, Oncology +17

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

Don Husereau, Michael Drummond, Stavros Petrou et al. · BMJ · 2013 · 1.8K citations · Full text

Public Affairs, Health Policy, Pharmacoeconomics +16

Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

Nasim Mavaddat, Susan Peock, Debra Frost et al. · JNCI Journal of the National Cancer Institute · 2013 · 939 citations

Medicine, Gynecology, Oncology +17

Generalized cost-effectiveness analysis for national-level priority-setting in the health sector

Raymond Hutubessy, Dan Chisholm, Tessa Tan-Torres Edejer · Cost Effectiveness and Resource Allocation · 2003 · 547 citations · Full text

Public Affairs, Health Policy, Cost-effectiveness Analysis +16

A new scoring system for the chances of identifying a <i>BRCA1/2</i> mutation outperforms existing models including BRCAPRO

D. Gareth Evans · Journal of Medical Genetics · 2004 · 265 citations · Full text

Life Sciences, Dermatology, Immunology +17